

W Claim:

1. A method for the preparation of a recombinant polypeptide comprising
 - a) transforming a host cell with an expression vector comprising:
 - (1) a nucleic acid sequence capable of regulating transcription in a host cell, operatively linked to
 - (2) a chimeric nucleic acid sequence encoding a fusion protein, the chimeric nucleic acid sequence comprising (a) a nucleic acid sequence encoding a chymosin pro-peptide, linked in reading frame to (b) a nucleic acid sequence heterologous to the pro-peptide and encoding the recombinant polypeptide, wherein the heterologous nucleic acid sequence is located immediately downstream of the nucleic acid sequence encoding the chymosin pro-peptide; operatively linked to
 - (3) a nucleic acid sequence encoding a termination region functional in said host cell,
 - b) growing the host cell to produce said fusion protein; and
 - c) adding a mature form of an autocatalytically maturing aspartic protease, that is capable of cleaving the chymosin pro-peptide, to the fusion protein so that the chymosin pro-peptide is cleaved from the fusion protein to release the recombinant polypeptide.
4. TheA method according to claim 1 wherein said aspartic protease added in step (c) is selected from the group consisting of chymosin, pepsin, HIV-1 protease, pepsinogen, cathepsin and yeast proteinase A.
5. TheA method according to claim 1 wherein the recombinant polypeptide is hirudin or carp growth hormone.
6. The method according to claim 1 wherein the chimeric nucleic acid sequence does not include a sequence encoding a mature form of chymosin.

- 2 -

7. TheA method according to claim 1 wherein the pH is from about 2 to about 4.5 ~~which further comprises altering the pH, altering the salt concentration or altering the temperature in step (c).~~

8. ~~A method according to claim 7 wherein the altering the pH comprises altering the pH to a pH from about 2 to about 4.5.~~

9. TheA method according to claim 1 wherein step (c) takes place under in vitro conditions.

10. TheA method according to claim 1 wherein step (c) takes place under in vivo conditions.

11. TheA method according to claim 10 wherein the in vivo conditions are those prevalent in a tissue or bodily fluid of an animal.

12. TheA method according to claim 11 wherein the tissue or bodily fluid comprises the milk, ~~blood, the stomach, or the gut or the kidneys of said animal.~~

13. TheA method according to claim 1 wherein the mature form of the aspartic protease added in step (c) is chymosin.

14. TheA method according to claim 1 wherein the aspartic protease added in step (c) is heterologous to the chymosin pro-peptide.

15. The method according to claim 13 wherein the chymosin is added under in vitro conditions.

16. The method according to claim 13 wherein the chymosin is added under in vivo conditions.

- 3 -

17. The method according to claim 16 wherein said in vivo conditions take place in a tissue or bodily fluid of an animal.
18. The method according to claim 17 wherein the tissue or bodily fluid is a stomach, ~~kidney, gut, blood or~~ milk of said animal.
19. TheA method according to claim 1 wherein said nucleic acid sequences are deoxyribonucleic acid (DNA) sequences.
- ✓20. A chimeric nucleic acid sequence encoding a fusion protein comprising (a) a nucleic acid sequence encoding a chymosin pro-peptide and (b) a nucleic acid sequence encoding a polypeptide that is heterologous to the chymosin pro-peptide, wherein the heterologous nucleic acid sequence is located immediately downstream of the nucleic acid sequence encoding the chymosin pro-peptide.
- ✓24. TheA chimeric nucleic acid sequence according to claim 20 wherein the polypeptide is hirudin or carp growth hormone.
- ✓25. TheA chimeric nucleic acid sequence according to claim 20 which does not include a sequence encoding a mature form of chymosin.
- ✓26. TheA chimeric nucleic acid sequence according to claim 20 wherein said nucleic acid sequences are deoxyribonucleic acid (DNA) sequences.
27. TheA chimeric nucleic acid sequence according to claim 26 wherein the chimeric sequence is as shown in SEQ.ID.NO 1. or SEQ. ID. NO. 3.
- ✓28. An expression vector comprising thea chimeric nucleic acid sequence according to claim 20 and a regulatory sequence suitable for expression in a host cell.

- 4 -

- ✓ 29. A transformed host cell containing ^{the} ~~an~~ expression vector according to claim 28.
- ✓ 30. A transformed host cell containing ^{the} ~~an~~ expression vector according to claim 28 wherein the host cell is a bacterial cell, a fungal cell, a plant cell or an animal cell.
- ✓ 41. A composition comprising a chimeric nucleic acid sequence encoding a fusion protein, the chimeric nucleic acid sequence comprising (a) a first nucleic acid sequence encoding a chymosin pro-peptide and (b) a second nucleic acid sequence encoding a polypeptide that is heterologous to the chymosin pro-peptide, wherein the heterologous nucleic acid sequence is located immediately downstream of the nucleic acid sequence encoding the chymosin pro-peptide.
42. A food composition comprising a chimeric nucleic acid sequence encoding a fusion protein, the chimeric nucleic acid sequence comprising (a) a first nucleic acid sequence encoding a chymosin pro-peptide and (b) a second nucleic acid sequence encoding a polypeptide that is heterologous to the chymosin pro-peptide, wherein the heterologous nucleic acid sequence is located immediately downstream of the nucleic acid sequence encoding the chymosin pro-peptide.
- ✓ 43. The A composition according to claim 41 wherein the nucleic acid sequences are deoxyribonucleic acid (DNA) sequences.
44. The A composition according to claim 41 wherein said chimeric nucleic acid sequence does not include a sequence encoding a mature form of chymosin.